Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.36 |
| ▸ | GBA1 | P04062 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 6/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | LCK | P06239 | 5/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571645 | 1.00 | JAK3 (0.36) | JAK3GBA1SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL1326323 | 0.79 | JAK3 (0.36) | JAK3GBA1SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL29600245 | 0.76 | JAK3 (0.35) | JAK3GBA1SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL24323944 | 0.76 | JAK3 (0.35) | JAK3GBA1SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL15908316 | 0.75 | JAK3 (0.43) | JAK3GBA1SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL24324142 | 0.75 | JAK3 (0.40) | JAK3GBA1SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL19947332 | 0.74 | CYP11B1 (0.35) | — | |
| SCHEMBL24325981 | 0.70 | POLB (0.44) | JAK3GBA1JAK1JAK2LCK | |
| SCHEMBL24324012 | 0.70 | TSHR (0.37) | JAK3LCK | |
| SCHEMBL29060237 | 0.68 | JAK3 (0.30) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | JAK3 4118/4885GBA1 702/4885SMN1; SMN2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.